OSR Holdings, Inc. (OSRH) 10-Year Financial Performance & Capital Metrics

OSRH • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutOSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.Show more

Revenue $0
EBITDA -$2M -319.4%
Net Income -$2M -697.1%
EPS (Diluted) -0.54 -1081.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -18.52% -3118.4%
ROIC -0.44% -108.9%
Debt/Equity -
Interest Coverage -81.95

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 38.9% through buybacks

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-95.1%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-77.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM6.69%

ROCE

10Y Avg-406.21%

5Y Avg-406.21%

3Y Avg-8.62%

Latest-23.36%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	23.81K	3.31K	35.39K	1.83M	3.52M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	23.81K	3.31K	35.39K	1.83M	3.52M
SG&A % of Revenue	-	-	-	-	-
Research & Development	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-23.81K	-3.31K	-35.39K	-1.83M	-3.52M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	0.86%	-9.7%	-50.73%	-0.93%
EBITDA+	-23.81K	-3.31K	-35.39K	944.59K	-2.07M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	0.86%	-9.7%	27.69%	-3.19%
D&A (Non-Cash Add-back)	0	0	0	0	0
EBIT	-23.81K	-3.31K	-35.39K	944.59K	-2.07M
Net Interest Income+	0	0	-12.27K	2.77M	1.41M
Interest Income	0	0	1.96K	2.77M	1.45M
Interest Expense	0	0	14.22K	0	43.01K
Other Income/Expense	0	0	0	2.78M	1.41M
Pretax Income+	-23.81K	-3.31K	-35.39K	944.59K	-2.12M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	540.81K	295.73K
Effective Tax Rate %	1%	1%	1%	0.43%	1.14%
Net Income+	-23.81K	-3.31K	-35.39K	403.78K	-2.41M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	0.86%	-9.7%	12.41%	-6.97%
Net Income (Continuing)	-23.81K	-3.31K	-35.39K	403.78K	-2.41M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.00	-0.00	-0.00	0.06	-0.54
EPS Growth %	-	-	-	-	-10.82%
EPS (Basic)	-0.00	-0.00	-0.00	0.06	-0.54
Diluted Shares Outstanding	7.89M	7.89M	8.49M	7.34M	4.48M
Basic Shares Outstanding	7.89M	7.89M	8.49M	7.34M	4.46M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	62.65K	4.76K	4.42M	22.63K	455.4K
Cash & Short-Term Investments	62.65K	4.76K	2.82M	15.42K	66.14K
Cash Only	62.65K	4.76K	2.82M	15.42K	66.14K
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	505.96K	1.54B	300K
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	1.08M	1.8B	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	0	-3.51B	89.26K
Total Non-Current Assets+	260.1K	700.33K	116.34M	36.61M	1.85M
Property, Plant & Equipment	0	0	371.6K	235.44M	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	12.13M	47.52B	0
Intangible Assets	0	0	103.59M	230.85B	0
Long-Term Investments	0	0	5.29K	7.95M	1.85M
Other Non-Current Assets	260.1K	700.33K	218.5K	-278.68B	0
Total Assets+	322.75K	705.09K	120.76M	36.63M	2.3M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	1.18%	170.27%	-0.7%	-0.94%
Total Current Liabilities+	321.56K	707.21K	5.86M	2.04M	6.72M
Accounts Payable	0	0	4.26M	1.08M	2.88M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	300K	400K	1.14M	500M	2.56M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	21.56K	307.21K	104.97K	-1.16B	0
Current Ratio	0.19x	0.01x	0.75x	0.01x	0.07x
Quick Ratio	0.19x	0.01x	0.57x	-884.37x	0.07x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	15.8M	2.07M	2.07M
Long-Term Debt	0	0	126.69K	460M	0
Capital Lease Obligations	0	0	247K	101.66M	0
Deferred Tax Liabilities	0	0	15.42M	43.33B	0
Other Non-Current Liabilities	0	0	0	-43.89B	2.07M
Total Liabilities	321.56K	707.21K	21.66M	4.11M	8.79M
Total Debt+	300K	400K	1.56M	1.17B	2.56M
Net Debt	237.35K	395.24K	-1.26M	1.17B	2.5M
Debt / Equity	252.53x	-	0.02x	35.90x	-
Debt / EBITDA	-	-	-	1235.97x	-
Net Debt / EBITDA	-	-	-	1235.95x	-
Interest Coverage	-	-	-2.49x	-	-81.95x
Total Equity+	1.19K	-2.12K	99.1M	32.52M	-6.49M
Equity Growth %	-	-2.78%	46745.49%	-0.67%	-1.2%
Book Value per Share	0.00	-0.00	11.67	4.43	-1.45
Total Shareholders' Equity	1.19K	-2.12K	99.1M	32.52M	-6.49M
Common Stock	173	173	4.6M	36.43M	1.85M
Retained Earnings	-23.81K	-27.12K	53.11K	-3.91M	-8.33M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	168.94M	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-23.81K	-461	-4.24K	-818.77K	-2.19M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	0.98%	-8.19%	-192.33%	-1.67%
Net Income	-23.81K	-3.31K	-35.39K	403.78K	-2.41M
Depreciation & Amortization	0	0	0	0	0
Stock-Based Compensation	0	0	0	0	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	0	0	-2.78M	-1.45M
Working Capital Changes	0	2.85K	31.15K	1.55M	1.67M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	0	1.8M
Cash from Investing+	0	0	0	-33.83M	35.91M
Capital Expenditures	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	155.66K
Cash from Financing+	86.47K	-57.44K	123.98K	34.54M	-33.67M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	7K	0	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-23.81K	-460	-4.24K	-818.77K	-2.19M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	0.98%	-8.22%	-192.11%	-1.67%
FCF per Share	-0.00	-0.00	-0.00	-0.11	-0.49
FCF Conversion (FCF/Net Income)	1.00x	0.14x	0.12x	-2.03x	0.91x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	461.96K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2004.38%	-	-0.07%	0.61%	-18.52%
Return on Invested Capital (ROIC)	-	-0.79%	-0.05%	-0.21%	-0.44%
Debt / Equity	252.53x	-	0.02x	35.90x	-
Interest Coverage	-	-	-2.49x	-	-81.95x
FCF Conversion	1.00x	0.14x	0.12x	-2.03x	0.91x

Frequently Asked Questions

Growth & Financials

OSR Holdings, Inc. (OSRH) reported $0.1M in revenue for fiscal year 2024.

OSR Holdings, Inc. (OSRH) grew revenue by 0.0% over the past year. Growth has been modest.

OSR Holdings, Inc. (OSRH) reported a net loss of $16.3M for fiscal year 2024.

Dividend & Returns

OSR Holdings, Inc. (OSRH) has a return on equity (ROE) of -18.5%. Negative ROE indicates the company is unprofitable.

OSR Holdings, Inc. (OSRH) had negative free cash flow of $1.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener